We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Moderna (MRNA) Q1 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Moderna (MRNA - Free Report) is expected to reveal quarterly loss of $3.59 per share, indicating a decline of 1989.5% compared to the year-ago period. Analysts forecast revenues of $124.74 million, representing a decrease of 93.3% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 17.7% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Moderna metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Revenue- Product sales' stands at $111.55 million. The estimate suggests a change of -93.9% year over year.
Based on the collective assessment of analysts, 'Revenue- Collaboration revenue' should arrive at $11.65 million. The estimate points to a change of +16.5% from the year-ago quarter.
Analysts' assessment points toward 'Revenue- Grant revenue' reaching $3.92 million. The estimate indicates a change of -83.7% from the prior-year quarter.
Moderna shares have witnessed a change of +1.3% in the past month, in contrast to the Zacks S&P 500 composite's -2% move. With a Zacks Rank #3 (Hold), MRNA is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unveiling Moderna (MRNA) Q1 Outlook: Wall Street Estimates for Key Metrics
The upcoming report from Moderna (MRNA - Free Report) is expected to reveal quarterly loss of $3.59 per share, indicating a decline of 1989.5% compared to the year-ago period. Analysts forecast revenues of $124.74 million, representing a decrease of 93.3% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 17.7% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Moderna metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Revenue- Product sales' stands at $111.55 million. The estimate suggests a change of -93.9% year over year.
Based on the collective assessment of analysts, 'Revenue- Collaboration revenue' should arrive at $11.65 million. The estimate points to a change of +16.5% from the year-ago quarter.
Analysts' assessment points toward 'Revenue- Grant revenue' reaching $3.92 million. The estimate indicates a change of -83.7% from the prior-year quarter.
View all Key Company Metrics for Moderna here>>>
Moderna shares have witnessed a change of +1.3% in the past month, in contrast to the Zacks S&P 500 composite's -2% move. With a Zacks Rank #3 (Hold), MRNA is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>